In idiopathic pulmonary fibrosis, 12 months of pulmonary rehabilitation increased cerebral oxygenation during exercise, ...

After providing pulmonary rehabilitation options for more than a decade to patients with a variety of lung conditions, Morris ...

Multidimensional intervention for patients with lung cancer incorporates rehabilitation, psychosocial support, nutrition guidance, health promotion, and safety surveillance. Multidimensional ...

Cereno Scientific (Nasdaq First North: CRNO B) ("the Company"), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, annou ...

Professional cardiology societies have issued an updated guideline for the management of adult patients with congenital heart ...

The larger cardiac rehab gym will accommodate up to 28 pieces of exercise equipment, a walking track surrounding the gym, ...

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more ...

Estimated YUTREPIA net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in Jun ...

Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the final patient has ...

Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking ...

Takeda & Protagonist submit NDA to US FDA seeking approval for rusfertide to treat polycythemia vera: Osaka, Japan Wednesday, January 7, 2026, 17:00 Hrs [IST] Takeda, focused on c ...

When professionals get it wrong, the consequences can range from awkward to genuinely alarming. This collection brings ...